Business
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020
Company to Host Business Update Conference Call at 4:30 pm ET HOUSTON, March 5, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Company to Host Business Update Conference Call at 4:30 pm ET\n\n\nHOUSTON, March 5, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, plans to report financial results for the three and 12 months ended December 31, 2019, after the close of the U.S. financial markets on Thursday, March 12, 2020. \n\n \n \n \n \n \n \n\n \nCNS' senior management will provide a business update in a conference call and live audio webcast at 4:30 p.m. Eastern time on Thursday, March 12, 2020. The conference call dial-in and webcast information is as follows: \nDOMESTIC DIAL-IN:\n(844) 535-4071\nINTERNATIONAL DIAL-IN:\n(706) 679-2458\nPASSCODE:\n1254059\nWEBCAST:\nCNS Business Update Conference Call\nFor those unable to participate in the live conference call or webcast, a replay will be available beginning approximately two hours after the close of the conference call. To access the replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 1254059. The replay can be accessed for a period of time on CNS website at CNS Business Update Conference Call.\nAbout CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatr...